The arrival of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable excitement within the healthcare community. This novel dual GIP and GLP-1 target medication appears to deliver significant improvements in weight shedding compared to previous therapies. Preliminary research data have shown significant declines in body fat percentage, p